NRC — National Research Share Price
0.000.00%
Last trade - 00:00- $244.26m
- $302.73m
- $143.06m
- 86
- 72
- 26
- 65
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.81 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 12.74 | ||
| Price to Sales | 1.71 | ||
| EV to EBITDA | 7.34 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 36.4% | ||
| Return on Equity | 61.77% | ||
| Operating Margin | 24.6% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 133.28 | 147.95 | 151.57 | 148.58 | 143.06 | n/a | n/a | 2.25% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +13.69 | +2.35 | +14.93 | -25.39 | -16.47 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights that facilitate measurement and improvement of the patient and employee experience while also increasing patient engagement and customer loyalty for healthcare organizations in the United States. Its digital solutions consist of four solution categories: Patient Experience, Consumer Experience, Employee Experience, and Market Experience, which can be implemented both collectively as an enterprise solution or individually to meet specific needs within the organization. Its Marketing solutions are subscription-based services that allow for improved tracking of awareness, perception, and consistency of healthcare brands; real-time assessment of competitive differentiators, and enhanced segmentation tools. Its Reputation solutions allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs better consumer decision-making.
Directors
- Michael Hays PRE (66)
- Kevin Karas CFO (63)
- Jona Raasch COO (62)
- Helen Hrdy OTH (56)
- John Nunnelly LED (68)
- Donald Berwick IND (74)
- Stephen Lockhart IND (62)
- JoAnn Martin IND (66)
- Penny Wheeler IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 30th, 2021
- Public Since
- October 1st, 1997
- No. of Shareholders
- 13,981
- No. of Employees
- 368
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 22,785,421
- Address
- 1245 Q Street, LINCOLN, 68508
- Web
- https://nrchealth.com/
- Phone
- +1 4024752525
- Auditors
- KPMG LLP
Upcoming Events for NRC
Q1 2025 National Research Corp Earnings Release
Q2 2025 National Research Corp Earnings Release
Similar to NRC
Acacia Research
NASDAQ Global Select Market
AvidXchange Holdings
NASDAQ Global Select Market
Barrett Business Services
NASDAQ Global Select Market
Casella Waste Systems
NASDAQ Global Select Market
Cass Information Systems
NASDAQ Global Select Market
FAQ
What is the National Research share price?
As of Today at 22:12 UTC, shares in National Research are trading at $10.72. This share price information is delayed by 15 minutes.
How has the National Research share price performed this year?
Shares in National Research last closed at $10.72 and the price had moved by -68.09% over the past 365 days. In terms of relative price strength the National Research share price has underperformed the S&P500 Index by -70.54% over the past year.
What are the analyst and broker recommendations for National Research?
The overall consensus recommendation for National Research is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the National Research dividend yield?
The National Research dividend yield is 4.48% based on the trailing twelve month period.
Does National Research pay a dividend?
Last year, National Research paid a total dividend of $0.48, and it currently has a trailing dividend yield of 4.48%. We do not have any data on when National Research is to next pay dividends.
When does National Research next pay dividends?
We do not have data on when National Research is to next pay dividends. The historic dividend yield on National Research shares is currently 4.48%.
How do I buy National Research shares?
To buy shares in National Research you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of National Research?
As of the previous close price of $10.72, shares in National Research had a market capitalisation of $244.26m.
Where are National Research shares listed?
Here are the trading details for National Research:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: NRC
What kind of share is National Research?
Based on an overall assessment of its quality, value and momentum National Research is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a National Research share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the National Research share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like National Research. Over the past six months, its share price has underperformed the S&P500 Index by -37.09%.
As of the last closing price of $10.72, shares in National Research were trading -41.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the National Research PE Ratio?
The National Research PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $10.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of National Research?
National Research's management team is headed by:
- Michael Hays - PRE
- Kevin Karas - CFO
- Jona Raasch - COO
- Helen Hrdy - OTH
- John Nunnelly - LED
- Donald Berwick - IND
- Stephen Lockhart - IND
- JoAnn Martin - IND
- Penny Wheeler - IND